|Podcasts|December 24, 2020

Episode 72: Trying to Outpace Rare Disease

Rich Horgan, founder and president of Cure Rare Disease (CRD), discusses how he sprang into action when his brother was diagnosed with Duchenne muscular dystrophy, by starting a nonprofit biotech to help find a cure.

Rich Horgan, founder and president of Cure Rare Disease(CRD), discusses how he sprang into action when his brother was diagnosed with Duchenne muscular dystrophy, by starting a nonprofit biotech to help find a cure.

You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.


Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.
Pharmaceutical Executive Daily
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.